First Interchangeability Designation Opens Doors For Biosimilars
Pharmacy Substitution For Semglee Now Possible Without Prescriber Intervention
An FDA decision to award Viatris a landmark interchangeability designation for its Semglee insulin glargine biosimilar has been welcomed by industry representatives.
